Literature DB >> 2787376

Prevalence of benign oesophageal disease in the Danish population with special reference to pulmonary disease.

L I Andersen1, G Jensen.   

Abstract

A population sample, selected at random after stratification for the presence of pulmonary disease, was examined for benign oesophageal disease by means of a mailed questionnaire, which has been described in a previous report. Eight hundred and nine subjects without pulmonary disease, 264 with chronic bronchitis, and 248 with bronchial asthma answered the questionnaire. Subjects answering affirmatively to a discriminating combination of questions, as well as some of the participants with single symptoms and randomly selected controls without oesophageal symptoms, were invited to a clinical examination (n = 346). One hundred and seventy-five subjects accepted an invasive investigation, 86 without pulmonary disease and 89 with chronic obstructive pulmonary disease (COPD). Endoscopy of the upper gastrointestinal tract was performed in 169 subjects, while 168 underwent pressure measurements of the oesophagus, and 113 had oesophageal 12-h pH measurements taken. On the basis of accepted definitions we found 114 subjects with benign oesophageal disease. The diagnostic sensitivity and specificity of the discriminating combination in the non-COPD and COPD groups were 73.9%/42.9% and 89.5%/47.1% respectively. The predictive accuracy of the questionnaire in the non-COPD and COPD group was 0.41 and 0.56, respectively. Prevalence rates of benign oesophageal disease in the non-COPD and the COPD groups were 34.5% (20-49%) and 44.5% (34-55%) respectively (P less than 0.001). We estimated the prevalence rate in the general population to be about 30%.

Entities:  

Mesh:

Year:  1989        PMID: 2787376     DOI: 10.1111/j.1365-2796.1989.tb00102.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

Review 1.  Comorbidities in chronic obstructive pulmonary disease.

Authors:  Wissam M Chatila; Byron M Thomashow; Omar A Minai; Gerard J Criner; Barry J Make
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

2.  Hospital discharges resulting from esophagitis among Medicare beneficiaries.

Authors:  A Sonnenberg; B T Massey; S J Jacobsen
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

3.  Gastro-oesophageal reflux disease increases the risk of intensive care unit admittance and mechanical ventilation use among patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study.

Authors:  Chen-Liang Tsai; Yu-Huei Lin; Meng-Ting Wang; Li-Nien Chien; Chii Jeng; Chih-Feng Chian; Wann-Cherng Perng; Chi-Huei Chiang; Hung-Yi Chiou
Journal:  Crit Care       Date:  2015-03-24       Impact factor: 9.097

Review 4.  Gastroesophageal reflux disease in COPD: links and risks.

Authors:  Annemarie L Lee; Roger S Goldstein
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-09-14

Review 5.  Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis.

Authors:  Thiago Mamôru Sakae; Márcia Margaret Menezes Pizzichini; Paulo José Zimermann Teixeira; Rosemeri Maurici da Silva; Daisson José Trevisol; Emilio Pizzichini
Journal:  J Bras Pneumol       Date:  2013 May-Jun       Impact factor: 2.624

6.  Prediction of acute respiratory disease in current and former smokers with and without COPD.

Authors:  Russell P Bowler; Victor Kim; Elizabeth Regan; André A A Williams; Stephanie A Santorico; Barry J Make; David A Lynch; John E Hokanson; George R Washko; Peter Bercz; Xavier Soler; Nathaniel Marchetti; Gerard J Criner; Joe Ramsdell; MeiLan K Han; Dawn Demeo; Antonio Anzueto; Alejandro Comellas; James D Crapo; Mark Dransfield; J Michael Wells; Craig P Hersh; Neil MacIntyre; Fernando Martinez; Hrudaya P Nath; Dennis Niewoehner; Frank Sciurba; Amir Sharafkhaneh; Edwin K Silverman; Edwin J R van Beek; Carla Wilson; Christine Wendt; Robert A Wise
Journal:  Chest       Date:  2014-10       Impact factor: 9.410

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.